Article Versions Notes

Artiaga BL, Madden D, Kwon T, McDowell C, Keating C, Balaraman V, de Carvahlo Madrid DM, Touchard L, Henningson J, Meade P, et al. Adjuvant Use of the Invariant-Natural-Killer-T-Cell Agonist α-Galactosylceramide Leads to Vaccine-Associated Enhanced Respiratory Disease in Influenza-Vaccinated Pigs. Vaccines. 2024; 12(9):1068. https://doi.org/10.3390/vaccines12091068

Artiaga, Bianca L., Daniel Madden, Taeyong Kwon, Chester McDowell, Cassidy Keating, Velmurugan Balaraman, Darling Melany de Carvahlo Madrid, Laurie Touchard, Jamie Henningson, Philip Meade, and et al. 2024. "Adjuvant Use of the Invariant-Natural-Killer-T-Cell Agonist α-Galactosylceramide Leads to Vaccine-Associated Enhanced Respiratory Disease in Influenza-Vaccinated Pigs" Vaccines 12, no. 9: 1068. https://doi.org/10.3390/vaccines12091068

Artiaga, B. L., Madden, D., Kwon, T., McDowell, C., Keating, C., Balaraman, V., de Carvahlo Madrid, D. M., Touchard, L., Henningson, J., Meade, P., Krammer, F., Morozov, I., Richt, J. A., & Driver, J. P. (2024). Adjuvant Use of the Invariant-Natural-Killer-T-Cell Agonist α-Galactosylceramide Leads to Vaccine-Associated Enhanced Respiratory Disease in Influenza-Vaccinated Pigs. Vaccines, 12(9), 1068. https://doi.org/10.3390/vaccines12091068